1 |
Van Zwieten, P.A., Hansson, L., Epstein, M., 1997. Slowly acting calcium antagonists and their merits. Blood Press. 6, 78-80.
DOI
|
2 |
Wacher, V.J., Salphati, L., Benet, L.Z., 2001. Active secretion and enterocytic drug metabolism barriers to drug absorption. Adv. Drug. Deliv. Rev. 46, 89-102.
DOI
|
3 |
Wang, E.J., Casciano, C.N., Clement, R.P., Johnson, W.W., 2000. Two transport binding sites of P-glycoprotein are unequal yet contingent: initial rate kinetic analysis by ATP hydrolysis demonstrates intersite dependence. Biochim. Biophys. Acta. 1481, 63-74.
DOI
ScienceOn
|
4 |
Lee, Y., Yeo, H., Liu, S.H., Jiang, Z., Savizky, R.M., Austin, D.J., Cheng, Y.C., 2004. Increased anti-P-glycoprotein activity of baicalein by alkylation on the A ring. J. Med. Chem. 47, 5555- 5566.
DOI
|
5 |
Lin, C.C., Shieh, D.E., 1996. The anti-inflammatory activity of Scutellaria rivularis extracts and its active components, baicalin, baicalein and wogonin. Am. J. Chin. Med. 24, 31-36.
DOI
|
6 |
Manach, C., Regerat, F., Texier, O., Agullo, G., Demigne, C., Remesy, C., 1996. Bioavailability, metabolism and physiological impact of 4-oxo-flavonoids. Nutrition Research 16, 517-544.
DOI
|
7 |
Saeki, T., Ueda, K., Tanigawara, Y., Hori, R., Komano, T., 1993. Pglycoprotein- mediated transcellular transport of MDR-reversing agents. FEBS Lett. 324, 99-102.
DOI
|
8 |
Matsuzaki, K., Kurokawa, N., Terai, S., Matsumura, Y., Kobayashi, N., Okita, K., 1996. Cell death induced by baicalein in human hepatocellular carcinoma cell lines. Jpn. J. Cancer Res. 87, 170-177.
DOI
|
9 |
Nijveldt, R.J., van Nood, E., van Hoorn, D.E., Boelens, P.G., van Norren, K., van Leeuwen, P.A., 2001. Flavonoids: a review of probable mechanisms of action and potential applications. Am. J. Clin. Nutr. 74, 418-425.
|
10 |
Piao, Y.J., Choi, J.S., 2008. Effects of morin on the pharmacokinetics of nicardipine after oral and intravenous administration of nicardipine in rats. J. Pharm. Pharmacol. 60, 625-629.
DOI
|
11 |
Sagara, K., Ito, Y., Oshima, T., Misaki, T., Murayama, H., 1985. Simultaneous determination of baicalein, wogonin, oroxylin-A and their glucuronides in Scutellariae radix by ion-pair highperformance liquid chromatography. J. Chromatogr. A 328, 289-297.
DOI
|
12 |
Takino, Y., Miyahara, T., Arichi, E., Arichi, S., Hayashi, T., Karikura, M., 1987. Determination of some flavonoids in Scutellariae radix by high-performance liquid chromatography. Chem. Pharm. Bull. 35, 3494-3497.
|
13 |
Guengerich, F.P., Martin, M.V., Beaune, P.H., Kremers, P., Wolff, T., Waxman, D.J., 1986. Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J. Biol. Chem. 261, 5051-5060.
|
14 |
Higuchi, S., Shiobara, Y., 1980. Metabolic fate of nicardipine hydrochloride, a new vasodilator, by various species in vitro. Xenobiotica 10, 889-896.
DOI
|
15 |
Kishi, Y., Okumura, F., Furuya, H., 1984. Haemodynamic effects of nicardipine hydrochloride. Studies during its use to control acute hypertension in anaesthetized patients. Br. J. Anaesth. 56, 1003-1007.
DOI
|
16 |
Hu, Y.P., Chapey, C., Robert, J., 1996. Relationship between the inhibition of azidopine binding to P-glycoprotein by MDR modulators and their efficiency in restoring doxorubicin intracellular accumulation. Cancer Lett. 109, 203-209.
DOI
|
17 |
Hysing, E.S., Chelly, J.E., Doursout, M.F., Hartley, C., Merin, R.G., 1986. Cardiovascular effects of and interaction between calcium blocking drugs and anesthetics in chronically instrumented dogs. III. Nicardipine and isoflurane. Anaesthesiology 65, 385-391.
DOI
|
18 |
Kaminsky, L.S., Fasco, M.J., 1991. Small intestinal cytochromes P450. Crit. Rev. Toxicol. 21, 407-422.
DOI
|
19 |
Kitagawa, S., Nabekura, T., Takahashi, T., Nakamura, Y., Sakamoto, H., Tano, H., Hirai, M., Tsukahara, G., 2005. Structureactivity relationships of the inhibitory effects of flavonoids on P-glycoprotein-mediated transport in KB-C2 cells. Biol Pharm Bull. 28, 2274-2278.
DOI
|
20 |
Kolars, J.C., Schmiedlin-Ren, P., Schuetz, J.D., Fang, C., Watkins, P.B., 1992. Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J. Clin. Invest. 90, 1871-1878.
DOI
|
21 |
Benet, L.Z., Cummins, C.L., Wu, C.Y., 2003. Transporter-enzyme interactions: implications for predicting drug-drug interactions from in vitro data. Curr. Drug Metab. 4, 393-398.
DOI
|
22 |
Dixon, R.A., Steele, C.L., 1999. Flavonoids and isoflavonoids-a gold mine for metabolic engineering. Trends Plant Sci. 4, 394- 400.
DOI
|
23 |
Choi, J.S., Choi, B.C., Kang, K.W., 2009. Effects of resveratrol on the pharmacokinetics of oral and intravenous nicardipine in rats. Pharmazie. 64, 49-52.
|
24 |
Crespi, C.L., Miller, V.P., Penman, B.W., 1997. Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450. Anal. Biochem. 248, 188-190.
DOI
|
25 |
Cummins, C.L., Jacobsen, W., Benet, L.Z., 2002. Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. J. Pharmacol. Exp. Ther. 300, 1036-1045.
DOI
|
26 |
Eastwood, R.J., Galustian, C., Bhamra, R.K., Holt, D.W., 1990. High-performance liquid chromatographic method for the measurement of nicardipine in plasma or serum. J. Chromatogr. 530, 463-468.
DOI
|
27 |
Graham, D.J., Dow, R.J., Freedman, D., Mroszczak, E., Ling, T., 1984. Pharmacokinetics of nicardipine following oral and intravenous administration in man. Postgrad. Med. J. 60, 7-10.
|
28 |
Graham, D.J., Dow, R.J., Hall, D.J., Alexander, O.F., Mroszczak, E.J., Freedman, D., 1985. The metabolism and pharmacokinetics of nicardipine hydrochloride in man. Br. J. Clin. Pharmacol. 20, 23-28.
DOI
|
29 |
Guengerich, F.P., 1991. Reactions and significance of cytochrome P-450 enzymes. J. Biol. Chem. 266, 10019-10022.
|